Vitamin D supplements are among the most-discussed "add-on" tools for type 2 diabetes. A new systematic review and meta-analysis of 18 randomized trials (about 2,000 people) found the effect is real but modest — hemoglobin A1c drops by an average of 0.42%, along with fasting glucose, insulin resistance, and markers of inflammation.
The authors pooled data from PubMed, Scopus, and Embase covering 2010 to 2026 and selected 18 randomized controlled trials (RCTs) — the gold standard of evidence-based medicine, in which participants are randomly assigned to a supplement group or a placebo group. In total, roughly 2,000 patients with diagnosed type 2 diabetes were included.
The work followed the PRISMA 2020 protocol, pooling results with a random-effects model (DerSimonian–Laird) and calculating the mean difference (MD) between groups. Robustness was tested with a leave-one-out approach (excluding each trial in turn) and with the GRADE scale, which rated the certainty of evidence as moderate to high.
Vitamin D significantly improved several metabolic measures at once. The key figures are the average difference between the supplement group and the control:
| Measure | Change (MD) | Heterogeneity I² |
|---|---|---|
| HbA1c (glycated hemoglobin) | −0.42% | 27% |
| Fasting blood glucose | −9.5 mg/dL (≈ −0.53 mmol/L) | 16% |
| HOMA-IR (insulin resistance) | −0.98 | 60% |
| C-reactive protein (inflammation) | −0.46 mg/L | 30% |
| LDL ("bad" cholesterol) | −5.85 mg/dL (≈ −0.15 mmol/L) | 22% |
| Triglycerides | −6.51 mg/dL (≈ −0.07 mmol/L) | 0% |
For scale: a 0.42% drop in HbA1c is roughly a third to half of the effect of metformin at a starting dose. On its own that is small, but combined with reduced inflammation (CRP) and insulin resistance (HOMA-IR), the picture becomes clinically meaningful. Low heterogeneity (I² of 0 to 30%) for most measures means the trials produced consistent results — which strengthens confidence in the conclusion.
Subgroup analysis showed the effect was strongest in patients from Asian populations — likely because of a higher baseline prevalence of vitamin D deficiency.
If you have type 2 diabetes and a confirmed vitamin D deficiency, a supplement may be a reasonable add-on to standard treatment — but an add-on, not a replacement for metformin, diet, and physical activity. By the logic of the data, the greatest benefit goes to those who are genuinely deficient.
These are pooled data from different trials with varying doses, durations, and baseline vitamin D status among participants — so the "mean difference" smooths over individual variation. For HOMA-IR the heterogeneity was high (I² = 60%), meaning the insulin-resistance results are less stable. The authors explicitly call the effect "modest but significant," not a breakthrough. And, of course, no supplement regimen should be changed without consulting your treating physician — high doses of vitamin D are not safe.
⚠ This is a preprint. The study is posted on Research Square and has not yet been peer-reviewed. The conclusions may change after expert review — treat the figures as preliminary.
NutriAI recognizes your meal from a photo and counts calories, protein, fat, and carbs in seconds — a handy nutrition tool for diabetes management and beyond.
Open @botnutraibot →